X4 Pharmaceuticals Q2 2026 Earnings: License Revenue Helps Narrow the Net Loss

X4 Pharmaceuticals (Nasdaq: XFOR) reported Q2 2026 revenue of $8.8 million, up from $2.0 million a year earlier, while basic and diluted net loss per share narrowed to $0.13 from $3.47. Net loss declined to $16.2 million from $25.7 million as Norgine-related license revenue increased and operating expenses decreased. U.S. XOLREMDI net product sales reached $2.4 million, while the company ended June with a stated $208.0 million cash position.

Core Financial Results

License and other revenue provided most of the quarterly increase. It rose by $6.2 million and accounted for approximately 91% of the overall year-over-year revenue gain, while XOLREMDI product revenue increased by approximately 36%.

Total operating expenses fell by 10.7%, helping narrow the operating and net losses. Gross margin declined modestly, however, because cost of revenue increased slightly faster than total revenue.

The per-share comparison was affected by a substantial change in the denominator: weighted-average shares outstanding increased to 126.3 million from 7.4 million. The improvement in loss per share therefore overstates the change in the underlying net loss.

Business and Clinical Program Performance

XOLREMDI commercialization and Norgine revenue

U.S. net product sales of XOLREMDI were $2.4 million, compared with $1.7 million in Q2 2025. Product sales represented approximately 27% of quarterly revenue, with the remaining 73% coming from license and other revenue.

The European Commission authorized XOLREMDI for patients with WHIM syndrome in the European Union. The authorization was transferred to Norgine in July 2026, and Norgine will lead European commercialization.

Under the license and supply agreement, X4 could receive up to an additional €221 million if specified regulatory and commercial milestones are achieved. The agreement also provides for escalating double-digit royalties of up to the mid-twenties on future net sales in licensed territories. These amounts remain contingent and are not recognized revenue guidance.

Phase 3 4WARD trial execution

X4 transferred management of the Phase 3 4WARD chronic neutropenia trial to a new clinical research organization as part of an overhaul of its clinical operating infrastructure. The company reported more than 110 active trial sites worldwide and continued using medical-affairs outreach and data-driven patient identification to support enrollment.

The current study description calls for 176 patients aged 12 and older. Management is revisiting the sample size with the FDA and expects to provide an update on the FDA meeting and enrollment completion by the end of the third quarter of 2026.

Profitability, Liquidity, and the Balance Sheet

R&D expense declined 17.8% to $15.1 million. X4 attributed the decrease primarily to lower headcount following its 2025 restructuring, partly offset by higher clinical expenses, especially costs associated with the new CRO supporting 4WARD.

G&A expense decreased 10.8% to $8.5 million. The company cited lower sales and marketing spending, reduced outside legal expenses, and lower compensation costs following headcount reductions.

X4’s stated $208.0 million cash position consisted of $195.1 million in cash and cash equivalents and $12.9 million in marketable securities. Combined cash and marketable securities declined by approximately $45.0 million during the first six months of 2026, while working capital decreased by $36.3 million.

Management said the balance sheet should provide a cash runway into 2029. The release did not provide quarterly operating or free cash flow figures, so the six-month decline in cash and securities should not be treated as a quarterly cash-flow measure.

Recent Insider Transactions

The transaction-level information provided reports two sales by CFO David H. Kirske Sr. during Q2 2026 and a purchase by executive and director Adam R. Craig in October 2025. The other seven most recent entries were zero-value stock awards rather than open-market transactions.

Risks Investors Should Monitor

• Revenue composition: License and other revenue drove most of the quarterly increase, while net product sales were only $2.4 million. This makes reported revenue sensitive to the timing and recognition of partnership-related payments.
• 4WARD execution: X4 changed CROs, overhauled its clinical infrastructure, and is discussing the trial’s sample size with the FDA. Enrollment timing or study-design changes could affect development progress and future spending.
• Continued losses and declining liquidity: Although the quarterly loss narrowed, X4 remained unprofitable and combined cash and marketable securities declined by approximately $45.0 million during the first half. Management’s runway estimate depends on future spending and operating outcomes.
• Contingent European economics: The potential €221 million of additional Norgine payments depends on regulatory and commercial milestones, while future royalties require successful commercialization in the licensed territories.

Summary

X4’s Q2 2026 results improved as Norgine-related license revenue increased and restructuring reduced R&D and G&A expenses, narrowing the net loss. U.S. XOLREMDI sales grew but remained a minority of total revenue, making the composition of future revenue important. The next major operational checkpoint is management’s expected third-quarter update on FDA discussions and enrollment completion for the Phase 3 4WARD trial, with the company’s $208.0 million cash position providing financial support for continued development.